Orthopaedics Inc. has chosen to sit a new president amidst a worldwide hip replacement recall and an impending mass litigation on its hip replacement systems. Andrew Ekdahl has replaced David Floyd, who resigned as company president, in the midst of lawsuits filed against the company alleging defective hip replacement implants.
Ekdahl who had spent more than two decades with DePuy and its parent, Johnson & Johnson of New Brunswick, N.J. is now expected to be on top of the company’s quality-control issues related to its hip products.
Last August, DePuy voluntarily recalled the ASR Hip Resurfacing and ASR XL Acetabular systems after data from the National Joint Registry of England and Wales showed that within five years, about 13 percent of patients with the acetabular system and 12 percent with the hip resurfacing system needed corrective surgery.
Ekdahl will lead the joint replacement and trauma company’s growing orthopedic operations and serve on the DePuy Franchise Global Management Board of the DePuy Family of Companies. DePuy Orthopaedics employs 1,200 in Warsaw, where it is based.
Danelle Miller, president of the board of directors for the Indiana Medical Device Manufacturers Council and legal counsel for global quality and regulatory affairs with Roche Diagnostics Corp., both in Indianapolis, said Ekdahl must contend with tighter regulatory scrutiny from the government.
Although it may take some time for a resolution on the replacements, DePuy showed resolve this month when it gained approval of a ceramic-on-metal hip implant system from the U.S. Food and Drug Administration.
According to the company, it expects the Pinnacle Complete Acetabular Hip System to offer “durability and stability, along with enhanced low-wear characteristics, that will provide surgeons with an important new option for patients with severe osteoarthritis.”
Read more about DePuy Announces New President Amidst Hip Replacement Recalls
Ekdahl who had spent more than two decades with DePuy and its parent, Johnson & Johnson of New Brunswick, N.J. is now expected to be on top of the company’s quality-control issues related to its hip products.
Last August, DePuy voluntarily recalled the ASR Hip Resurfacing and ASR XL Acetabular systems after data from the National Joint Registry of England and Wales showed that within five years, about 13 percent of patients with the acetabular system and 12 percent with the hip resurfacing system needed corrective surgery.
Ekdahl will lead the joint replacement and trauma company’s growing orthopedic operations and serve on the DePuy Franchise Global Management Board of the DePuy Family of Companies. DePuy Orthopaedics employs 1,200 in Warsaw, where it is based.
Danelle Miller, president of the board of directors for the Indiana Medical Device Manufacturers Council and legal counsel for global quality and regulatory affairs with Roche Diagnostics Corp., both in Indianapolis, said Ekdahl must contend with tighter regulatory scrutiny from the government.
Although it may take some time for a resolution on the replacements, DePuy showed resolve this month when it gained approval of a ceramic-on-metal hip implant system from the U.S. Food and Drug Administration.
According to the company, it expects the Pinnacle Complete Acetabular Hip System to offer “durability and stability, along with enhanced low-wear characteristics, that will provide surgeons with an important new option for patients with severe osteoarthritis.”
Read more about DePuy Announces New President Amidst Hip Replacement Recalls
RSS Feed